Brolucizumab 6 mg
Sponsors
Novartis Pharmaceuticals
Conditions
Age-related Macular DegenerationBranch Retinal Vein OcclusionCentral Retinal Vein OcclusionNeovascular Age-related Macular DegenerationProliferative Diabetic Retinopathy
Phase 3
Study of Safety and Efficacy of Brolucizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD
CompletedNCT03386474
Start: 2018-01-15End: 2018-09-06Updated: 2021-01-05
Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Branch Retinal Vein Occlusion
TerminatedNCT03802630
Start: 2019-07-02End: 2021-07-26Updated: 2023-01-30
Assessing the Efficacy and Safety of Brolucizumab Versus Aflibercept in Patients With Visual Impairment Due to Macular Edema Secondary to Central Retinal Vein Occlusion
TerminatedNCT03810313
Start: 2019-07-03End: 2021-07-26Updated: 2023-01-30
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)
CompletedNCT04005352
Start: 2019-09-25End: 2022-09-09Updated: 2024-10-09
Study of Efficacy and Safety of Brolucizumab Versus Panretinal Photocoagulation Laser in Patients With Proliferative Diabetic Retinopathy
CompletedNCT04278417
Start: 2020-11-19End: 2024-08-19Updated: 2025-10-16